NSPRHealthcare · Medical DevicesThe 3 Wall Street analysts covering InspireMD, Inc. hold a median 12-month price target of $3 — +564.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores InspireMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (93): Analysts have, on balance, been raising their forecasts.
Value (1): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NSPR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +564.6% from it.
Of the 11 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 May 2026 | Piper Sandler | Reiterates | Overweight | $4.00 → $3.00 |
| 12 May 2025 | Piper Sandler | Maintains | Overweight | — |
| 11 Dec 2024 | Lake Street | Initiates | Buy | — |
| 17 Sept 2024 | Piper Sandler | Reiterates | Overweight | $4.50 |
| 2 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 12 June 2023 | Piper Sandler | Initiates | Overweight | — |
| 17 May 2023 | National Alliance Securities | Maintains | Buy | — |
| 31 Mar 2023 | Alliance Global Partners | Maintains | Buy | — |
| 16 Oct 2020 | Alliance Global Partners | Initiates | Buy | $0.70 |
| 11 Mar 2020 | HC Wainwright & Co. | Reiterates | Buy | $5.00 → $2.00 |
| 29 Mar 2016 | Rodman & Renshaw | Maintains | Buy | $4.00 → $3.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NSPR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, InspireMD, Inc. returned −80.1% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 52% of US stocks
Cheaper than 79% of US stocks
Cheaper than 61% of US stocks
Higher than 27% of US stocks
Higher than 36% of US stocks
Higher than 2% of US stocks
Higher than 6% of US stocks
Higher than 88% of US stocks
Higher than 7% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
InspireMD, Inc. has a market value of $21.4M and an enterprise value of −$6.2M.
Revenue in the twelve months to 30 June 2026: $10.8M. The latest quarter shrank 0.4% year on year.
Net income over the same four quarters: −$52.5M, a −484.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.64.
Free cash flow in the twelve months to 30 June 2026: −$42.5M.
Trailing P/E: −0.6×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
InspireMD, Inc. employs 127 people — $85K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own InspireMD, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
InspireMD announced it will release its third-quarter 2026 financial results on November 12, 2026. The company will host a conference call and webcast at 8:30 a.m. in conjunction with the release.
Why it matters — NSPR watchers can note the scheduled date and time for the company’s quarterly results and related discussion.
InspireMD announced amendments to certain Series J and Series K warrants that align their trigger event with the anticipated FDA approval of the CGuard Prime 80 cm, which the company continues to expect in Q4 2026. The amendments could provide potential gross proceeds of up to $11 million.
Why it matters — NSPR watchers would care because the warrant amendments tie potential capital to the anticipated CGuard Prime 80 cm FDA approval timeline, which is a key milestone for the company.
InspireMD's Compensation Committee approved inducement grants of 23,764 shares of restricted stock to a new non-executive employee, with a grant date of September 2, 2026, issued outside the company's 2021 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — This announcement provides a brief update on InspireMD's equity compensation and hiring activity, which may be of interest to NSPR watchers monitoring corporate governance and staffing developments.
InspireMD, Inc. announced plans to present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The company develops the CGuard Prime carotid stent system for stroke prevention.
Why it matters — NSPR watchers would care because the company is increasing investor visibility by presenting at a major investment conference.
InspireMD (NSPR) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade signals increased confidence in the company's near-term outlook.
Why it matters — A Zacks upgrade to Buy indicates improved analyst sentiment on InspireMD's earnings outlook, which NSPR watchers would consider a favorable signal.
The 3 Wall Street analysts covering InspireMD, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering InspireMD, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InspireMD, Inc. 53 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, InspireMD, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (93 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +564.6% from the last close, and Ticker Nerd's factor model ranks InspireMD, Inc. 53 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering InspireMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NSPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.
InspireMD, Inc. returned -80.1% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
InspireMD, Inc. is a medical device company that develops and commercializes products for the treatment of carotid artery disease and other vascular conditions.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "InspireMD to Announce Third Quarter 2026 Financial Results". InspireMD announced it will release its third-quarter 2026 financial results on November 12, 2026. The company will host a conference call and webcast at 8:30 a.m. in conjunction with the release.
InspireMD, Inc. is a medical device company that develops and commercializes products for the treatment of carotid artery disease and other vascular conditions. The company’s portfolio centers on its proprietary CGuard™ carotid stent platform and MicroNet™ mesh technology, which are designed to support embolic protection during and after stenting procedures. InspireMD’s current products include carotid embolic prevention and stent systems used in vascular and neurovascular interventions, with applications across stroke prevention and related artery treatment settings. The company serves physicians, hospitals, and healthcare providers in multiple international markets, including the United States and select regions in Europe, the Middle East, Latin America, and Asia Pacific. InspireMD plays a specialized role in the medical technology market by focusing on device-based solutions for complex carotid and coronary care.
CEO Mr. Marvin L. Slosman · 127 employees · United States · https://www.inspiremd.com
